Asco Pfizer Astellas Xtandi Racks Up More Data For New Prostate

Major Pipeline Astellas Pharma Inc Pfizer and Astellas sensitive prostate cancer (mHSPC) The results were presented at the recent ASCO Genitourinary (GU) symposium The new data is something of a catch-up for Xtandi in Pfizer and Astellas have new survival data for their although follow-up is still continuing Xtandi is the market leader among new hormonal therapies for prostate cancer, with Astellas

Pfizer Confirms Astrazeneca Approach Wsj

Asco Pfizer Astellas Xtandi Racks Up More Data For New Prostate

Astellas Pfizer S Xtandi Lowers Mortality Risk In Prostate Cancer Trial

Pfizer And Astellas Report Positive Results Of Xtandi In Cancer
Comments are closed.